Molecular Targeting of Plaque Angiogenesis in Diabetes
Molecular Targeting of Plaque Angiogenesis in Diabetes
批准号:
8097905
负责人:
KAREN Simpson MOULTON
金额:
$22.59万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2013-03-31
关键词:
AccelerationAdverse drug effectAffinityAngiogenesis InhibitorsAnimal ModelAreaArterial Fatty StreakArteriesAtherosclerosisBindingBlood VesselsBlood capillariesBlood flowCaliberCell Adhesion MoleculesCell ProliferationCellsCollaborationsColoradoDataDevelopmentDiabetes MellitusDiabetic RetinopathyDiabetic macrovascular diseaseDiagnosticDrug Delivery SystemsDyslipidemiasEndotheliumFunctional disorderFutureGoalsGrowthHemorrhageHeterogeneityHigh PrevalenceHomingHyperglycemiaHyperplasiaHypertensionImageImmuneIndividualInflammatoryInjuryInsulin-Dependent Diabetes MellitusIntegrinsInvadedKnowledgeLigandsLungMalignant NeoplasmsMediatingMethodsMiningModelingMolecularMolecular TargetMonitorMyocardial InfarctionPathologicPathologic NeovascularizationPatientsPenetrationPeptidesPermeabilityPhage DisplayPharmaceutical PreparationsPlasma CellsProliferatingPropertyProteinuriaReceptor ActivationRetinal DiseasesRoleRuptureSchoolsSeminalSirolimusStrokeTechnologyTestingThrombosisTissuesTunica AdventitiaValidationVascular Endothelial Growth Factor ReceptorVascular Endothelial Growth FactorsVascular PermeabilitiesVasculitisabstractingangiogenesiscapillarycostdiabetichigh riskin vivomacrovascular diseasemolecular imagingnanoparticleneovascularneovascularizationnon-diabeticnovelreceptortargeted deliverytreatment responsevasa vasorumvascular bed
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Networks of small caliber blood vessels, termed vasa vasorum, are confined to the outer media and adventitia layers of major large caliber blood vessels; however, these vessels proliferate and invade the intima during atherosclerosis and other conditions of vasculitis. Increasing data suggests that the permeability, inflammatory cell recruitment and bleeding properties of plaque neovascularization promote atherosclerosis and its complications. The neovascular network invading atherosclerotic lesions may also serve as a more efficient portal for drug penetration into diseased arteries to control their occlusion and plaque instability. In diabetes, we have recently shown the tendency for plaques to acquire neovascularization is significantly increased and accelerates atherosclerosis. Thus, the characterization of molecules displayed on plaque neovascularization in diabetes can identify important ligand/receptor interactions that take place on this unique microvascular endothelium and mediate pathologic functions. These molecular targets can be exploited to deliver molecular imaging agents or drugs to the pathologic neovascularization and minimize their effects on normal arteries. We hypothesize angiogenic plaque capillaries display unique molecules that promote atherosclerosis in diabetes, which will useful to understand and modify its functions and to deliver more selective treatments. Our preliminary studies have identified a receptor that is highly expressed on plaque neovascularization, but not on the endothelium or normal arteries. We will use receptor-specific targeting peptides that have been optimized by our collaborators to validate ligand-directed nanoparticle delivery to diabetic plaque neovascularization in vivo. We will also use a novel animal model of diabetes-induced plaque angiogenesis and phage display methods to screen and identify a repertoire of vascular- accessible, high affinity ligand/receptor partners on plaque neovascularization in diabetes. Results from this exploratory study will enhance our molecular understanding of plaque vasa vasorum and its role in progression of atherosclerosis and vascular complications. Our screen should identify other plaque neovascularization binding candidates and will refine methods for in vivo validation of plaque angiogenesis-dependent targeting that will drive future development of targeting agents for diagnostics and treatments to reduce macrovascular complications in patients with or without diabetes.
PUBLIC HEALTH RELEVANCE: The goals of this project will demonstrate a more precise means to deliver drugs or imaging agents to unique areas of abnormal blood vessel growth that contribute to vascular complications and cause heart attacks and strokes, particularly for patients with diabetes. Results may reduce costs and side effects of drugs by concentrating drugs in the tissues where they are most needed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Targeting of Plaque Angiogenesis in Diabetes
-
批准号:8266401
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2011
-
负责人:KAREN Simpson MOULTON
-
依托单位:
Urinary MMP activity biomarkers for early diabetic renal dysfunction
-
批准号:8046269
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2010
-
负责人:KAREN Simpson MOULTON
-
依托单位:
Endogenous Regulators of Plaque Angiogenesis
-
批准号:6321448
-
项目类别:
-
资助金额:$29.22万
-
财政年份:2001
-
负责人:KAREN Simpson MOULTON
-
依托单位:
Endogenous Regulators of Plaque Angiogenesis
-
批准号:6787663
-
项目类别:
-
资助金额:$30.08万
-
财政年份:2001
-
负责人:KAREN Simpson MOULTON
-
依托单位:
Endogenous Regulators of Plaque Angiogenesis
-
批准号:6528017
-
项目类别:
-
资助金额:$30.17万
-
财政年份:2001
-
负责人:KAREN Simpson MOULTON
-
依托单位:
Endogenous Regulators of Plaque Angiogenesis
-
批准号:6612865
-
项目类别:
-
资助金额:$30.12万
-
财政年份:2001
-
负责人:KAREN Simpson MOULTON
-
依托单位:
REGULATION OF MACROPHAGE DEVELOPMENT
-
批准号:2210185
-
项目类别:
-
资助金额:$8.38万
-
财政年份:1991
-
负责人:KAREN Simpson MOULTON
-
依托单位:
REGULATION OF MACROPHAGE DEVELOPMENT
-
批准号:2210182
-
项目类别:
-
资助金额:$8.29万
-
财政年份:1991
-
负责人:KAREN Simpson MOULTON
-
依托单位:
REGULATION OF MACROPHAGE DEVELOPMENT
-
批准号:2210184
-
项目类别:
-
资助金额:$7.62万
-
财政年份:1991
-
负责人:KAREN Simpson MOULTON
-
依托单位:
REGULATION OF MACROPHAGE DEVELOPMENT
-
批准号:3087798
-
项目类别:
-
资助金额:$8.02万
-
财政年份:1991
-
负责人:KAREN Simpson MOULTON
-
依托单位:
REGULATION OF MACROPHAGE DEVELOPMENT
-
批准号:3087797
-
项目类别:
-
资助金额:$7.39万
-
财政年份:1991
-
负责人:KAREN Simpson MOULTON
-
依托单位: